In the overall Asthma and COPD market, Advair remained the market leader with USD 7,802 million in 2011 and is expected to reach USD xxxx million in 2014. Singulair is the second largest drug in terms of revenue at UD 5479 million in 2011. The patent that provides U.S. market exclusivity for Singulair will expire in August 2012. It is expected that within 2-3 years following patent expiration, it will lose substantially all U.S. sales of Singulair, with most of those declines coming in the first full year following patent expiration. Also, the patent that provides market exclusivity for Singulair will expire in a number of major European markets in February 2013 and sales of Singulair in those markets will decline significantly thereafter. The patent that provides market exclusivity for Singulair in Japan will expire in 2016.
Asia Pacific region commanded for the largest share of global Asthma patients in 2010. The North America region will have the fastest growth rate for asthma patients at a CAGR of 3.9% in the world during 2010 - 2017. Globally, patients numbers are increasing continuously primarily due to cigarette smoking, continual exposure to hazardous particles or gases, increase in urbanization, change in lifestyle, and genetic factors. The growing number of asthmatics people from china and other economies will drive the revenue growth for the Asthma and COPD drugs market.
At present, long-acting beta2 agonist (LABA) / inhaled corticosteroid (ICS) combinations are the preferred combinations in the U.S. for treatment of asthma and/or COPD that include Advair (GlaxoSmithKline), Symbicort (AstraZeneca), and Dulera (Merck). LABA/ICS combinations are the most prescribed drugs because they offer efficacy and the convenience of delivering two drugs in one inhaler. The U.S. sales for asthma and COPD drugs are expected to total more than USDxxxx billion in 2012.
In Europe, LABA / ICS combinations and LTA (Montelukast) drugs are more popular for asthma and COPD treatment. Merck's branded product Singulair contains Montelukast sodium, which is a leading oral anti-asthma and anti-allergy drug. Singulair is one of the trusted drugs for the treatment of chronic asthma, and for the relief of symptoms of seasonal allergic rhinitis. Currently, Montelukast is the largest selling anti-asthmatic drug worldwide.
For COPD patients, physicians also prescribe use of the long-acting muscarinic antagonist (LAMA) Spiriva (Boehringer Ingelheim/Pfizer). Spiriva is expected to constitute about xxx% of the U.S. COPD drug sales in 2012. The LABA/LAMA combination is preferred for the treatment of COPD. Several combinations are in late-stage development, including vilanterol / GSK-573719 (GlaxoSmithKline/Theravance), indacaterol / glycopyrronium (Novartis), and olodaterol / tiotropium (Boehringer Ingelheim).
Key products exposed to generic competition include GlaxoSmithKline’s Advair Boehringer Ingelheim/Pfizer’s Spiriva and Merck’s Singulair, which will lose active ingredient patent protection in the U.S. in 2011 and 2012 respectively. Patent expiration of Merck’s Singulair, which generated sales of around USD 3.3 billion in 2010, will be a key restraint for the overall Asthma market as generic entry in the United States, Europe and Japan will reduce sales of branded Singulair.
Asthma is characterized by recurrent attacks of coughing, chest-tightening, breathlessness and wheezing as the airways narrow and swell that vary in severity and frequency. This chronic disease is most common among children.
CHAPTER 1 INTRODUCTION
1.1 REPORT DESCRIPTION
1.2 SCOPE OF THE REPORT
1.3 METHODOLOGY
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 ASTHMA AND COPD MARKET
3.1 MARKET OVERVIEW
3.2 INCREASING ASTHMA AND COPD PREVALENCE AND TRENDS
3.2.1 Region wise estimate of asthma patients, 2007-2011(Million)
3.2.1 Region wise Estimate of COPD patients, 2007-2011 (Million)
3.3 PRODUCT TREND ANALYSIS
3.4 ASTHMA DISEASE OVERVIEW
3.4.1 ASTHMA PATIENT FORECASTS BY GEOGRAPHY, 2012 - 2017 (MILLION)
3.4.2 PATIENTS SUFFERING FROM ASTHMA, CHINA, 2012 - 2017 (MILLION)
3.5 COPD DISEASE OVERVIEW
3.6 PATIENT FORECASTS – COPD PATIENTS BY GEOGRAPHY, 2012 – 2017 (MILLION)
3.6.1 PATIENTS SUFFERING FROM COPD, CHINA, 2010 - 2017 (MILLION)
3.7 GROWTH DRIVERS
3.7.1 INCREASE IN POPULATION SUSCEPTIBLE TO INDOOR AIR POLLUTANTS
3.7.2 DAILY EXPOSURE TO HAZARDOUS WORKING ENVIRONMENT LEADS TO GROWTH OF ASTHMA AND COPD
3.7.3 GROWING AGING POPULATION
3.7.4 INCREASING POPULATION OF SMOKERS WILL SUPPORT THE GROWTH OF ASTHMA AND COPD MARKET
3.7.5 INFLUX OF POLLUTANTS IN THE AIR
3.7.6 INCREASE IN DISPOSABLE INCOME AND HEALTHCARE FACILITY
3.8 MARKET RESTRAINTS
3.8.1 PATENT EXPIRY OF MANY BLOCKBUSTER BRANDS WILL CREATE PRESSURE
3.8.2 OVERALL HIGH COST OF ASTHMA TREATMENT IS A CHALLENGE FOR PATIENTS
3.8.2.1 Uninsured people - a challenge
3.8.3 LONG TREATMENT CONTINUATION
3.9 PORTER FIVE FORCES MODEL
3.9.1 BARGAINING POWER OF SUPPLIER
3.9.2 BARGAINING POWER OF BUYER
3.9.3 RIVALRY AMONG EXISTING COMPETITORS
3.9.4 THREAT OF NEW ENTRANTS
3.9.5 THREAT OF SUBSTITUTE PRODUCTS OR SERVICES
CHAPTER 4 ASTHMA AND COPD MARKET BY PRODUCT TYPE
4.1 ASTHMA AND COPD DRUG REVENUE FORECASTS
4.2 BRONCHODILATORS
4.2.1 REVENUE FORECASTS FOR BRONCHODILATORS
4.2.2 SHORT ACTING BRONCHODILATORS
4.2.2.1 Revenue Forecasts for Short-Acting Bronchodilators
4.2.3 LONG-ACTING BRONCHODILATORS
4.2.3.1 Revenue Forecasts for Long-Acting Bronchodilators
4.2.4 ANTICHOLINERGICS BRONCHODILATORS
4.2.4.1 Revenue Forecasts Anticholinergics
4.3 ANTI-INFLAMMATORIES
4.3.1.1 Revenue Forecasts for Anti-Inflammatories
4.3.2 INHALED CORTICOSTEROIDS
4.3.2.1 Revenue Forecasts for Inhaled Corticosteroids
4.3.3 ANTI-LEUKOTRIENES
4.3.3.1 Revenue Forecasts for Anti-Leukotrienes
4.3.4 MONOCLONAL ANTIBODIES
4.3.4.1 Revenue Forecasts for Monoclonal Antibodies
4.4 COMBINATION THERAPIES
4.4.1 REVENUE FORECASTS FOR COMBINATION THERAPIES
CHAPTER 5 ASTHMA DRUG MARKET ANALYSIS
5.1 ASTHMA DRUG MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)
5.2 ASTHMA PATHOPHYSIOLOGY
5.3 ASTHMA DRUG REVENUE BY BRNAD, 2009 - 2011 (USD MILLION)
5.3.1 MEDICATION
5.3.1.1 Short-Acting Beta2-Agonists
5.3.1.2 Inhaled Corticosteroids
5.3.1.3 Long-Acting Bronchodilators
5.3.1.4 Leukotriene Modifiers
5.3.1.5 Mast Cell Stabilizers
5.3.1.6 Methyxanthines
5.3.1.7 Monoclonal Antibodies
5.3.1.8 Oral Corticosteroids
5.4 ADHERENCE
5.4.1 MEDICATION ADHERENCE BY AGE GROUP, 2011
5.5 ASTHMA - COST TRENDS
5.6 EMERGING TREATMENT OPTIONS FOR ASTHMA
CHAPTER 6 COPD MARKET ANALYSIS
6.1 COPD DRUG MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)
6.2 COPD DRUG MARKET BY CATEGORY, 2009 – 2012 (USD MILLION)
6.3 EXISTING MEDICATION FOR COPD
6.4 COPD DRUG MARKET SHARE 2011 VS 2017
6.4.1 BRONCHODILATORS
6.4.2 LONG-ACTING ANTICHOLINERGICS
6.4.3 LONG-ACTING Β2-AGONISTS
6.4.4 SHORT-ACTING BRONCHODILATORS
6.5 INHALED CORTICOSTEROIDS
6.6 COMBINATION THERAPIES
6.6.1 Β2-AGONISTS AND ANTICHOLINERGICS
6.6.2 LABAS AND INHALED CORTICOSTEROIDS
6.7 EMERGING TRENDS IN COPD THERAPY
CHAPTER 7 DRUG BRAND DYNAMICS
7.1 ADVAIR/SERETIDE REVENUE (USD MILLION), 2009 - 2014
7.2 SYMBICORT REVENUE (USD MILLION), 2009 – 2014
7.3 SPIRIVA REVENUE (USD MILLION), 2009 - 2014
7.4 SINGULAIR REVENUE (USD MILLION), 2009 - 2014
CHAPTER 8 COMPETITIVE LANDSCAPE
8.1 COMPETITIVE STRATEGY BY KEY PLAYERS
8.2 MARKET SHARE BY KEY PLAYERS, 2011
8.3 KEY ASTHMA & COPD DRUGS BY REVENUE, 2009 – 2011 (USD MILLION)
CHAPTER 9 COMPANY PROFILE
9.1 NOVARTIS AG
9.1.1 COMPANY OVERVIEW
9.1.2 FINANCIAL OVERVIEW:
9.1.3 RESPIRATORY DIVISION NET SALES
9.1.4 SEGMENT OVERVIEW
9.1.5 GEOGRAPHICAL OVERVIEW
9.1.6 RECENT DEVELOPMENT
9.2 MERCK & CO.
9.2.1 COMPANY OVERVIEW
9.2.2 FINANCIAL OVERVIEW:
9.2.3 GEOGRAPHICAL OVERVIEW
9.2.4 RECENT DEVELOPMENT
9.3 GLAXOSMITHKLINE PLC
9.3.1 COMPANY OVERVIEW
9.3.2 FINANCIAL OVERVIEW:
9.3.3 SEGMENT OVERVIEW
9.3.4 GEOGRAPHICAL OVERVIEW
9.3.5 RECENT DEVELOPMENT
9.4 BOEHRINGER INGELHEIM GMBH (BOEHRINGER)
9.4.1 COMPANY OVERVIEW
9.4.2 FINANCIAL OVERVIEW:
9.4.3 SEGMENT OVERVIEW
9.4.4 GEOGRAPHICAL OVERVIEW
9.4.5 RECENT DEVELOPMENT
9.5 NYCOMED
9.5.1 COMPANY OVERVIEW
9.5.2 FINANCIAL OVERVIEW:
9.5.3 GEOGRAPHICAL OVERVIEW
9.5.4 RECENT DEVELOPMENT
LIST OF FIGURES
FIG. 1 REGION WISE ESTIMATE OF ASTHMA PATIENTS, 2007-2011 (MILLION)
FIG. 2 REGION WISE ESTIMATE OF COPD PATIENTS, 2007-2011 (MILLION)
FIG. 3 CHINESE ASTHMA PATIENTS POPULATION TREND, 2010 - 2017 (MILLION)
FIG. 4 CHINESE COPD PATIENTS POPULATION TREND, 2010 - 2017 (MILLION)
FIG. 5 AIR POLLUTION MARKET SHARE FROM DIFFERENT INDUSTRIES
FIG. 6 CHILDREN AGED (0-18) UNINSURED PERCENTAGE, 2003 - 2010
FIG. 7 ASTHMA AND COPD DRUG MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)
FIG. 8 BRONCHODILATORS MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)
FIG. 9 SHORT-ACTING BRONCHODILATORS MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)
FIG. 10 LONG-ACTING BRONCHODILATORS MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)
FIG. 11 ANTICHOLINERGICS MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)
FIG. 12 ANTI-INFLAMMATORIES MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)
FIG. 13 INHALED CORTICOSTEROIDS MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)
FIG. 14 ANTI-LEUKOTRIENES MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)
FIG. 15 MONOCLONAL ANTIBODIES MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)
FIG. 16 COMBINATION THERAPIES MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)
FIG. 17 ASTHMA DRUG MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)
FIG. 18 ASTHMA DRUG REVENUE BY BRNAD, 2009- 2011 (USD MILLION)
FIG. 19 MEDICATION ADHERENCE BY AGE GROUP, 2011
FIG. 20 COPD DRUG MARKET SIZE AND FORECAST, 2010 - 2017 (USD MILLION)
FIG. 21 COPD DRUG MARKET BY CATEGORY, 2009 – 2012 (USD MILLION)
FIG. 22 COPD DRUG MARKET SHARE 2011 VS 2017
FIG. 23 ADVAIR/SERETIDE REVENUE (USD MILLION), 2009 - 2014
FIG. 24 SYMBICORT REVENUE (USD MILLION), 2009 - 2014
FIG. 25 SPIRIVA REVENUE (USD MILLION), 2009 - 2014
FIG. 26 SINGULAIR REVENUE (USD MILLION), 2009 - 2014
FIG. 27 PULMICORT REVENUE (USD MILLION), 2009 - 2014
FIG. 28 MARKET SHARE BY KEY PLAYERS, 2011
FIG. 29 NOVARTIS AG, PERFORMANCE CHART (2007-2011)
FIG. 30 NOVARTIS AG, MARKET SHARE BY SEGMENT IN 2011
FIG. 31 NOVARTIS AG, MARKET SHARE BY GEOGRAPHY IN 2011
FIG. 32 MERCK & CO. , PERFORMANCE CHART (2007-2011)
FIG. 33 MERCK & CO. MARKET SHARE BY GEOGRAPHY IN 2011
FIG. 34 GLAXOSMITHKLINE PLC AG, PERFORMANCE CHART (2006-2010)
FIG. 35 GLAXOSMITHKLINE PLC AG, MARKET SHARE BY SEGMENT IN 2010
FIG. 36 GLAXOSMITHKLINE PLC AG, MARKET SHARE BY GEOGRAPHY IN 2011
FIG. 37 BOEHRINGER INGELHEIM, MARKET SHARE BY SEGMENT IN 2011
FIG. 38 BOEHRINGER INGELHEIM, MARKET SHARE BY GEOGRAPHY IN 2011
FIG. 39 NYCOMED, MARKET SHARE BY GEOGRAPHY IN 2010
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Asthma and COPD Drug Market
*86 figures and 60 tables includes